Nuclear Legumain Activity in Colorectal Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Haugen, Mads H ^a,b   Johansen, Harald T ^c   Pettersen, Solveig J ^a   Solberg, Rigmor ^c   Brix, Klaudia ^b   Flatmark, Kjersti ^a   Maelandsmo, Gunhild M ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b JACOBS UNIVERSITY BREMEN   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L; HISTONE H3; LEGUMAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HCT116; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYSTEINE ENDOPEPTIDASES; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR LOCALIZATION SIGNALS; PROTEOLYSIS; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84872241498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052980     Document Type: Article

References (58)

1. Rawlings ND, Barrett AJ, Bateman A, (2010) MEROPS: the peptidase database. Nucleic Acids Res 38: D227-233.
2. Kembhavi AA, Buttle DJ, Knight CG, Barrett AJ, (1993) The Two Cysteine Endopeptidases of Legume Seeds: Purification and Characterization by Use of Specific Fluorometric Assays. Arch Biochem Biophys 303: 208-213.
3. Hara-Nishimura I, Takeuchi Y, Nishimura M, (1993) Molecular Characterization of a Vacuolar Processing Enzyme Related to a Putative Cysteine Proteinase of Schistosoma mansoni. Plant Cell 5: 1651-1659.
4. Chen JM, Dando PM, Rawlings ND, Brown MA, Young NE, et al. (1997) Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem 272: 8090-8098.
5. Dall E, Brandstetter H, (2012) Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile. Acta Crystallogr F 68: 24-31.
6. Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C, (2003) Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem 278: 38980-38990.
7. Ishidoh K, Kominami E, (2002) Processing and activation of lysosomal proteinases. Biol Chem 383: 1827-1831.
8. Cheng T, Hitomi K, van Vlijmen-Willems IM, de Jongh GJ, Yamamoto K, et al. (2006) Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem 281: 15893-15899.
9. Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dando PM, Ni J, et al. (1999) Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site. J Biol Chem 274: 19195-19203.
10. Liu C, Sun C, Huang H, Janda K, Edgington T, (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63: 2957-2964.
11. Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF, (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11: 2293-2299.
12. Gawenda J, Traub F, Luck HJ, Kreipe H, von Wasielewski R, (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 102: 1-6.
13. Briggs J, Haugen M, Johansen H, Riker A, Abrahamson M, et al. (2010) Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer 10: 17.
14. Shirahama-Noda K, Yamamoto A, Sugihara K, Hashimoto N, Asano M, et al. (2003) Biosynthetic Processing of Cathepsins and Lysosomal Degradation Are Abolished in Asparaginyl Endopeptidase-deficient Mice. J Biol Chem 278: 33194-33199.
15. Chan C-B, Abe M, Hashimoto N, Hao C, Williams IR, et al. (2009) Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc Natl Acad Sci U S A 106: 468-473.
16. Miller G, Matthews SP, Reinheckel T, Fleming S, Watts C, (2011) Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J 25: 1606-1617.
17. Andrade V, Guerra M, Jardim C, Melo F, Silva W, et al. (2011) Nucleoplasmic calcium regulates cell proliferation through legumain. J Hepatol 55: 626-635.
18. Chen JM, Fortunato M, Stevens RA, Barrett AJ, (2001) Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem 382: 777-783.
19. Liu Y, Bajjuri KM, Liu C, Sinha SC, (2011) Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug. Mol Pharmaceut 9: 168-175.
20. Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, et al. (2011) Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed: Nanotechnol 7: 665-673.
21. Øverbye A, Sætre F, Hagen LK, Johansen HT, Seglen PO, (2011) Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain. Autophagy 7: 1011-1027.
22. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, et al. (1998) An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396: 695-699.
23. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, et al. (2009) Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic Cells. Immunity 31: 737-748.
24. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, et al. (1976) Human Colonic Adenocarcinoma Cells. I. Establishment and Description of a New Line. In Vitro 12: 180-191.
25. Chantret I, Rodolosse A, Barbat A, Dussaulx E, Brot-Laroche E, et al. (1994) Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation. Journal of Cell Science 107: 213-225.
26. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad O, (2004) Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 40: 1593-1598.
27. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
28. Brix K, Lemansky P, Herzog V, (1996) Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology 137: 1963-1974.
29. Johansen HT, Knight CG, Barrett AJ, (1999) Colorimetric and fluorimetric microplate assays for legumain and a staining reaction for detection of the enzyme after electrophoresis. Anal Biochem 273: 278-283.
30. Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF, (2008) Visualizing protease activity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol Chapter 4: Unit 4 20.
31. Schneider CA, Rasband WS, Eliceiri KW, (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
32. Zeeuwen PL, van Vlijmen-Willems IM, Olthuis D, Johansen HT, Hitomi K, et al. (2004) Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice. Hum Mol Genet 13: 1069-1079.
33. Zeeuwen PLJM, van Vlijmen-Willems IMJJ, Cheng T, Rodijk-Olthuis D, Hitomi K, et al. (2010) The cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea. FASEB J pp. fj.10-155879.
34. Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, et al. (2003) Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 200: 589-595.
35. Yamane T, Takeuchi K, Yamamoto Y, Li YH, Fujiwara M, et al. (2002) Legumain from bovine kidney: its purification, molecular cloning, immunohistochemical localization and degradation of annexin II and vitamin D-binding protein. Biochim Biophys Acta 1596: 108-120.
36. Chen JM, Fortunato M, Barrett AJ, (2000) Activation of human prolegumain by cleavage at a C-terminal asparagine residue. Biochem J 352 Pt 2: 327-334.
37. Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, et al. (2009) Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer 125: 54-61.
38. Duncan EM, Muratore-Schroeder TL, Cook RG, Garcia BA, Shabanowitz J, et al. (2008) Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation. Cell 135: 284-294.
39. Jedeszko C, Sloane BF, (2005) Cysteine cathepsins in human cancer. Biol Chem 385: 1017-1027.
40. Lecaille F, Muno D, Kominami E, Ishidoh K, (2005) Proteinases participating in the processing and activation of prolegumain in primary cultured rat macrophages. Biol Chem 385: 511-516.
41. Ni J, Abrahamson M, Zhang M, Fernandez MA, Grubb A, et al. (1997) Cystatin E is a Novel Human Cysteine Proteinase Inhibitor with Structural Resemblance to Family 2 Cystatins. J Biol Chem 272: 10853-10858.
42. Sotiropoulou G, Anisowicz A, Sager R, (1997) Identification, Cloning, and Characterization of Cystatin M, a Novel Cysteine Proteinase Inhibitor, Down-regulated in Breast Cancer. J Biol Chem 272: 903-910.
43. Zeeuwen PL, Cheng T, Schalkwijk J, (2009) The Biology of Cystatin M/E and its Cognate Target Proteases. J Invest Dermatol 129: 1327-1338.
44. Brix K, Dunkhorst A, Mayer K, Jordans S, (2008) Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90: 194-207.
45. Patel N, Krishnan S, Offman MN, Krol M, Moss CX, et al. (2009) A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 119: 1964-1973.
46. Ong PC, McGowan S, Pearce MC, Irving JA, Kan W-T, et al. (2007) DNA Accelerates the Inhibition of Human Cathepsin V by Serpins. Journal of Biological Chemistry 282: 36980-36986.
47. Kosugi S, Hasebe M, Tomita M, Yanagawa H, (2009) Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci USA 106: 10171-10176.
48. Jordans S, Jenko-Kokalj S, Kuhl N, Tedelind S, Sendt W, et al. (2009) Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochemistry 10: 23.
49. Wu B, Yin J, Texier C, Roussel M, Tan KS, (2009) Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme. J Biol Chem 285: 1790-1798.
50. Kamada S, Kikkawa U, Tsujimoto Y, Hunter T, (2005) Nuclear Translocation of Caspase-3 Is Dependent on Its Proteolytic Activation and Recognition of a Substrate-like Protein(s). J Biol Chem 280: 857-860.
51. Zou H, McGarry TJ, Bernal T, Kirschner MW, (1999) Identification of a Vertebrate Sister-Chromatid Separation Inhibitor Involved in Transformation and Tumorigenesis. Science 285: 418-422.
52. Goulet B, Baruch A, Moon N-S, Poirier M, Sansregret LL, et al. (2004) A Cathepsin L Isoform that Is Devoid of a Signal Peptide Localizes to the Nucleus in S Phase and Processes the CDP/Cux Transcription Factor. Mol Cell 14: 207-219.
53. Goulet B, Sansregret L, Leduy L, Bogyo M, Weber E, et al. (2007) Increased Expression and Activity of Nuclear Cathepsin L in Cancer Cells Suggests a Novel Mechanism of Cell Transformation. Mol Cancer Res 5: 899-907.
54. Tedelind S, Poliakova K, Valeta A, Hunegnaw R, Yemanaberhan EL, et al. (2010) Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol Chem 391: 923-935.
55. Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, et al. (2012) Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Biochimie 94 (12):: 2590-2599.
56. Maehr R, Hang HC, Mintern JD, Kim YM, Cuvillier A, et al. (2005) Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. J Immunol 174: 7066-7074.
57. Liu Z, Jang S-W, Liu X, Cheng D, Peng J, et al. (2008) Neuroprotective Actions of PIKE-L by Inhibition of SET Proteolytic Degradation by Asparagine Endopeptidase. Mol Cell 29: 665-678.
58. Herskowitz JH, Gozal YM, Duong DM, Dammer EB, Gearing M, et al. (2012) Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics 12: 2455-2463.